- Karyopharm Therapeutics' (KPTI) Selinexor "showed preliminary evidence of anti-cancer activity as a single agent" in most relapsed/refractory NHL and CLL patients from a cohort comprised of those with progressive disease on entry.
- Data summary from the Phase 1 trial in advanced hematologic malignancies: PRs, 27%; SD, 50%; tumor shrinkage in 17 of 18 patients. (PR)
Karyopharm presents Selinexor data at ASH
Dec 9 2013, 08:26 ET